Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14
pubmed:dateCreated
2007-4-11
pubmed:databankReference
pubmed:abstractText
Type 1 diabetes mellitus (DM) results from a cell-mediated autoimmune attack against pancreatic beta cells. Previous animal and clinical studies suggest that moderate immunosuppression in newly diagnosed type 1 DM can prevent further loss of insulin production and can reduce insulin needs.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1538-3598
pubmed:author
pubmed:issnType
Electronic
pubmed:day
11
pubmed:volume
297
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1568-76
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:17426276-Adolescent, pubmed-meshheading:17426276-Adult, pubmed-meshheading:17426276-Autoantibodies, pubmed-meshheading:17426276-C-Peptide, pubmed-meshheading:17426276-Diabetes Mellitus, Type 1, pubmed-meshheading:17426276-Female, pubmed-meshheading:17426276-Glutamate Decarboxylase, pubmed-meshheading:17426276-Hematopoietic Stem Cell Mobilization, pubmed-meshheading:17426276-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:17426276-Hemoglobin A, Glycosylated, pubmed-meshheading:17426276-Hemoglobins, pubmed-meshheading:17426276-Humans, pubmed-meshheading:17426276-Immunosuppression, pubmed-meshheading:17426276-Insulin, pubmed-meshheading:17426276-Male, pubmed-meshheading:17426276-Prospective Studies, pubmed-meshheading:17426276-Transplantation, Autologous, pubmed-meshheading:17426276-Transplantation Conditioning
pubmed:year
2007
pubmed:articleTitle
Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
pubmed:affiliation
Department of Clinical Medicine, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. jcvoltar@fmrp.usp.br
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I